BCL-2 Is Consistently Expressed in Hyperplastic Marginal Zones of the Spleen, Abdominal Lymph Nodes, and Ileal Lymphoid Tissue

Meda, Brenton A.; Frost, Michael; Newell, James; Bohling, Sandra D.; Huebner-Chan, David R.; Perkins, Sherrie L.; Lim, Megan S.; Medeiros, L. Jeffrey; Elenitoba-Johnson, Kojo S.J.

doi:10.1097/00000478-200307000-00003

Cited by 21 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, one should be mindful of the differential diagnosis of marginal zone hyperplasia, which can present in both nodal and extranodal sites. 20–22…”

Section: Discussionmentioning

confidence: 99%

Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR

et al. 2010

View full text Add to dashboard Cite

Marginal zone lymphomas present rarely in children and young adults as either primary nodal or extranodal disease and have an excellent prognosis. To date, chromosomal aberrations have not been analyzed in the pediatric and young adult population. We undertook a study to analyze genetic alterations in nodal and extranodal marginal zone lymphomas in children and young adults using fluorescence in situ hybridization (FISH) and RT-PCR. These findings were correlated with clinical features at presentation and immunophenotype. Forty-one cases were identified meeting these criteria. The age range was 1.5-29 years old with 49% of the cases o18 years of age. 73% of the marginal zone lymphoma cases showed evidence of light chain restriction by immunohistochemistry or flow cytometry. CD43 was coexpressed in 83%. 85% of the marginal zone lymphoma cases tested showed evidence of immunoglobulin heavy chain gene rearrangement. Fifty-nine percent of the cases were nodal marginal zone lymphomas with a median age at presentation of 16 years and an M/F ratio of 7:1. Twenty-one percent of the nodal marginal zone lymphoma cases contained genetic aberrations. Seventeen percent contained trisomy 18 with one case containing an additional trisomy 3. A translocation of the immunoglobulin heavy chain gene to an unknown partner gene was present in one case. Forty-one percent of the cases were extranodal marginal zone lymphomas with a median age of 24 years and a M/F ratio of 1.4:1. Eighteen percent of the extranodal marginal zone lymphoma cases contained genetic aberrations. The t(14;18) involving the IGH and MALT1 genes was present in one case, tetraploidy was present in one case, and another case contained trisomy 3. Overall the incidence of genetic aberrations in marginal zone lymphomas in the pediatric and young adult population is low, but the aberrations seen are similar to those seen in the adult population.

show abstract

“…Nevertheless, one should be mindful of the differential diagnosis of marginal zone hyperplasia, which can present in both nodal and extranodal sites. 20–22…”

Section: Discussionmentioning

confidence: 99%

Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR

et al. 2010

View full text Add to dashboard Cite

show abstract

“…A small subset of mantle cell lymphoma (MCL) have increased expression of BCL-2 (33). Additionally, BCL-2 can also become overexpressed in the indolent MZL (32). For patient samples of both MCL and MZL, BCL-2 overexpression is reportedly caused by non-genomic changes to BCL-2 (33, 108).…”

Section: Bcl-2 Protein Family and Apoptosismentioning

confidence: 99%

Targeting the Bcl-2 Family in B Cell Lymphoma

et al. 2019

View full text Add to dashboard Cite

Although lymphoma is a very heterogeneous group of biologically complex malignancies, tumor cells across all B cell lymphoma subtypes share a set of underlying traits that promote the development and sustain malignant B cells. One of these traits, the ability to evade apoptosis, is essential for lymphoma development. Alterations in the Bcl-2 family of proteins, the key regulators of apoptosis, is a hallmark of B cell lymphoma. Significant efforts have been made over the last 30 years to advance knowledge of the biology, molecular mechanisms, and therapeutic potential of targeting Bcl-2 family members. In this review, we will highlight the complexities of the Bcl-2 family, including our recent discovery of overexpression of the anti-apoptotic Bcl-2 family member Bcl-w in lymphomas, and describe recent advances in the field that include the development of inhibitors of anti-apoptotic Bcl-2 family members for the treatment of B cell lymphomas and their performance in clinical trials.

show abstract

“…This translocation deregulates the coding sequence of the BCL2 gene (18q21) through its juxtaposition to the IGH locus at 14q32, leading to an overexpression of the antiapoptotic protein BCL-2 [2]. As BCL-2 protein expression is not specific for malignancy, the histopathologic diagnosis of FL can be difficult and may require t(14;18) detection [3]. However, the t(14;18) is not specific for FL and can be observed in diffuse large B-cell lymphomas and Burkitt or atypical Burkitt lymphoma/leukemia [4,5].…”

Section: Introductionmentioning

confidence: 99%

Interphase fluorescence in situ hybridization is more sensitive than BIOMED-2 polymerase chain reaction protocol in detecting IGH-BCL2 rearrangement in both fixed and frozen lymph node with follicular lymphoma

et al. 2007

View full text Add to dashboard Cite

BCL-2 Is Consistently Expressed in Hyperplastic Marginal Zones of the Spleen, Abdominal Lymph Nodes, and Ileal Lymphoid Tissue

Cited by 21 publications

References 21 publications

Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR

Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR

Targeting the Bcl-2 Family in B Cell Lymphoma

Interphase fluorescence in situ hybridization is more sensitive than BIOMED-2 polymerase chain reaction protocol in detecting IGH-BCL2 rearrangement in both fixed and frozen lymph node with follicular lymphoma

Contact Info

Product

Resources

About